Cibc World Market Inc. lowered its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 40.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,382 shares of the medical device company’s stock after selling 39,799 shares during the period. Cibc World Market Inc.’s holdings in DexCom were worth $5,124,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after acquiring an additional 1,515,702 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after purchasing an additional 645,534 shares in the last quarter. Legal & General Group Plc bought a new position in shares of DexCom during the 2nd quarter valued at about $173,237,000. Arrowstreet Capital Limited Partnership raised its holdings in DexCom by 100.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares during the period. Finally, Deutsche Bank AG acquired a new stake in DexCom during the 2nd quarter worth approximately $164,035,000. Institutional investors and hedge funds own 97.75% of the company’s stock.
Analyst Upgrades and Downgrades
DXCM has been the topic of a number of research reports. Citigroup lifted their price target on shares of DexCom from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Sunday, September 6th. Truist Financial set a $102.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, September 18th. Sanford C. Bernstein upped their target price on shares of DexCom from $77.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Barclays increased their target price on DexCom from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of “Buy” and a consensus target price of $95.50.
DexCom Stock Performance
Shares of DXCM opened at $79.32 on Friday. The stock has a market capitalization of $29.58 billion, a price-to-earnings ratio of 31.11, a PEG ratio of 1.31 and a beta of 1.45. DexCom, Inc. has a 12 month low of $56.72 and a 12 month high of $92.59. The firm has a fifty day simple moving average of $83.94 and a 200 day simple moving average of $75.41. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49.
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.68 by $0.05. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The firm had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the firm posted $0.61 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. Research analysts forecast that DexCom, Inc. will post 2.68 EPS for the current fiscal year.
Insider Buying and Selling
In related news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $78.62, for a total transaction of $201,660.30. Following the completion of the transaction, the executive vice president directly owned 120,913 shares of the company’s stock, valued at approximately $9,506,180.06. This represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the transaction, the executive vice president owned 146,828 shares of the company’s stock, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 22,822 shares of company stock worth $1,920,193. Insiders own 0.28% of the company’s stock.
DexCom Company Profile
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Further Reading
- Five stocks we like better than DexCom
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
